{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:34:11Z","timestamp":1747204451300,"version":"3.40.5"},"posted":{"date-parts":[[2022,11,11]]},"group-title":"In Review","reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,11,1]]},"abstract":"<title>Abstract<\/title>\n        <p>Detection of secretory antibodies in the airway is highly desirable when evaluating mucosal protection by a vaccine against a respiratory virus like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We show that a single intranasal delivery of an attenuated SARS-CoV-2 (Nsp1-K164A\/H165A) induced both mucosal and systemic IgA and IgG in Syrian hamsters. Interestingly, either active or passive immunization of hamsters with Nsp1-K164A\/H165A offered protection against heterologous challenge with variants of concern (VOCs) including Delta, Omicron BA.1, and Omicron BA.2.12.1. Among challenged animals, Nsp1-K164A\/H165A vaccination specifically reduced viral loads in the respiratory tract and suppressed infection-induced macrophage accumulation and MX1 upregulation in the lung. The absence of variant-specific mucosal and systemic antibodies was associated with breakthrough infections, particularly of the nasal cavity following challenges with Omicron isolates. Together, our study demonstrates that an attenuated nasal vaccine may be developed to boost mucosal immunity against future SARS-CoV-2 VOCs.<\/p>","DOI":"10.21203\/rs.3.rs-2227555\/v1","type":"posted-content","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T22:31:46Z","timestamp":1668205906000},"source":"Crossref","is-referenced-by-count":1,"title":["Active and Passive Immunization of Syrian Hamsters with An Attenuated SARS-CoV-2 Protects against New Variants of Concern"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8983-1721","authenticated-orcid":false,"given":"Tony","family":"Wang","sequence":"first","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Stauft","sequence":"additional","affiliation":[{"name":"Food and Drug Administration"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-3928","authenticated-orcid":false,"given":"Prabhuanand","family":"Selvaraj","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-9490","authenticated-orcid":false,"given":"Felice","family":"D'agnillo","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement","family":"Meseda","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotou","family":"Sangare","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyntia","family":"Pedro","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-6041","authenticated-orcid":false,"given":"Shufeng","family":"Liu","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-887X","authenticated-orcid":false,"given":"Christopher","family":"Lien","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Weir","sequence":"additional","affiliation":[{"name":"FDA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Starost","sequence":"additional","affiliation":[{"name":"Division of Veterinary Resources, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603\u20132615, doi:10.1056\/NEJMoa2034577 (2020).","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384, 403\u2013416, doi:10.1056\/NEJMoa2035389 (2021).","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant","volume":"603","author":"Suzuki R","year":"2022","unstructured":"Suzuki, R. et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700\u2013705, doi:10.1038\/s41586-022-04462-1 (2022).","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele S","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656, doi:10.1038\/s41586-021-04387-1 (2022).","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"Hui KPY","year":"2022","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715\u2013720, doi:10.1038\/s41586-022-04479-6 (2022).","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.15585\/mmwr.mm7105e1","article-title":"SARS-CoV-2 Infection and Hospitalization Among Adults Aged >\/=18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022","volume":"71","author":"Danza P","year":"2022","unstructured":"Danza, P. et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged >\/=18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep 71, 177\u2013181, doi:10.15585\/mmwr.mm7105e1 (2022).","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews N","year":"2022","unstructured":"Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 386, 1532\u20131546, doi:10.1056\/NEJMoa2119451 (2022).","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin ME","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 22, 1435\u20131443, doi:10.1016\/S1473-3099(22)00345-0 (2022).","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","author":"Tartof SY","year":"2022","unstructured":"Tartof, S. Y. et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. The Lancet Infectious Diseases, doi:https:\/\/doi.org\/10.1016\/S1473-3099(22)00692-2 (2022).","journal-title":"The Lancet Infectious Diseases"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar","volume":"386","author":"Abu-Raddad LJ","year":"2022","unstructured":"Abu-Raddad, L. J. et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med 386, 1804\u20131816, doi:10.1056\/NEJMoa2200797 (2022).","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin DR","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944, doi:10.1016\/S0140-6736(22)00152-0 (2022).","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S1473-3099(22)00292-4","article-title":"Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study","volume":"22","author":"Monge S","year":"2022","unstructured":"Monge, S. et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. Lancet Infect Dis 22, 1313\u20131320, doi:10.1016\/S1473-3099(22)00292-4 (2022).","journal-title":"Lancet Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2210546","article-title":"Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants","author":"Qu P","year":"2022","unstructured":"Qu, P. et al. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med, doi:10.1056\/NEJMc2210546 (2022).","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4853","author":"Tang J","year":"2022","unstructured":"Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci Immunol, eadd4853, doi:10.1126\/sciimmunol.add4853 (2022)."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.24.477597","article-title":"Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses","author":"Tianyang Mao BI","year":"2022","unstructured":"Tianyang Mao, B. I., Alexandra Suberi, Liqun Zhou, Melanie Reschke, Mario A Pe\u00f1a-Hern\u00e1ndez, Huiping Dong, Robert J Homer, W Mark Saltzman, Akiko Iwasaki. Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses. bioRxiv, doi:10.1101\/2022.01.24.477597 (2022).","journal-title":"bioRxiv"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"eadd9947","DOI":"10.1126\/sciimmunol.add9947","article-title":"Operation Nasal Vaccine-Lightning speed to counter COVID-19","volume":"7","author":"Topol EJ","year":"2022","unstructured":"Topol, E. J. & Iwasaki, A. Operation Nasal Vaccine-Lightning speed to counter COVID-19. Sci Immunol 7, eadd9947, doi:10.1126\/sciimmunol.add9947 (2022).","journal-title":"Sci Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer F","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527, doi:10.1038\/s41586-020-2798-3 (2020).","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"Amanat F","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 52, 583\u2013589, doi:10.1016\/j.immuni.2020.03.007 (2020).","journal-title":"Status Report. Immunity"},{"author":"release C","key":"ref19","unstructured":"release, C. p. https:\/\/codagenix.com\/codagenix-intranasal-COVID-19-19-vaccine-shows-potent-cellular-immune-response-against-conserved-viral-proteins-indicating-potential-for-immunogenicity-against-omicron-and-future-variants-in-phase-1-dat\/."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang Y","year":"2021","unstructured":"Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc Natl Acad Sci U S A 118, doi:10.1073\/pnas.2102775118 (2021).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"198074","DOI":"10.1016\/j.virusres.2020.198074","article-title":"The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway","volume":"286","author":"Li JY","year":"2020","unstructured":"Li, J. Y. et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res 286, 198074, doi:10.1016\/j.virusres.2020.198074 (2020).","journal-title":"Virus Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0221621","DOI":"10.1128\/jvi.02216-21","article-title":"Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen","volume":"96","author":"Liu S","year":"2022","unstructured":"Liu, S., Chou, C. K., Wu, W. W., Luan, B. & Wang, T. T. Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen. J Virol 96, e0221621, doi:10.1128\/jvi.02216-21 (2022).","journal-title":"J Virol"},{"year":"2022","author":"Liu S","key":"ref23","unstructured":"Liu, S., C. B. S., Prabhuanand Selvaraj, Prabha Chandrasekaran, Felice DAgnillo, Chao-Kai Chou, Wells W. Wu, Christopher Z. Lien, Clement A. Meseda, Cyntia L. Pedro, Matthew F. Starost, Jerry P. Weir, Tony T. Wang. Intranasal Delivery of a Rationally Attenuated SARS-CoV-2 Is Immunogenic and Protective in Syrian Hamsters Nature Communications Accepted (2022)."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"eabj5129","DOI":"10.1126\/sciimmunol.abj5129","article-title":"Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA","volume":"6","author":"Oh JE","year":"2021","unstructured":"Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci Immunol 6, eabj5129, doi:10.1126\/sciimmunol.abj5129 (2021).","journal-title":"Sci Immunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/infdis\/jiab587","article-title":"SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters","volume":"225","author":"Halfmann PJ","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. J Infect Dis 225, 282\u2013286, doi:10.1093\/infdis\/jiab587 (2022).","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"eabq3059","DOI":"10.1126\/scitranslmed.abq3059","article-title":"SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery","volume":"14","author":"Frere JJ","year":"2022","unstructured":"Frere, J. J. et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Sci Transl Med 14, eabq3059, doi:10.1126\/scitranslmed.abq3059 (2022).","journal-title":"Sci Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0050721","DOI":"10.1128\/mSphere.00507-21","article-title":"SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection","author":"Nunez IA","year":"2021","unstructured":"Nunez, I. A. et al. SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection. mSphere, e0050721, doi:10.1128\/mSphere.00507-21 (2021).","journal-title":"mSphere"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.05.022","author":"Zhang Z","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451 e2417, doi:10.1016\/j.cell.2022.05.022 (2022)."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1126\/science.abl8487","article-title":"COVID-19 vaccine breakthrough infections","volume":"374","author":"Gupta RK","year":"2021","unstructured":"Gupta, R. K. & Topol, E. J. COVID-19 vaccine breakthrough infections. Science 374, 1561\u20131562, doi:10.1126\/science.abl8487 (2021).","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.027","author":"Siddle KJ","year":"2022","unstructured":"Siddle, K. J. et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. Cell 185, 485\u2013492 e410, doi:10.1016\/j.cell.2021.12.027 (2022)."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani M","year":"2021","unstructured":"Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 21, 475\u2013484, doi:10.1038\/s41577-021-00578-z (2021).","journal-title":"Nat Rev Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"eabn6868","DOI":"10.1126\/scitranslmed.abn6868","article-title":"Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model","volume":"14","author":"Langel SN","year":"2022","unstructured":"Langel, S. N. et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med 14, eabn6868, doi:10.1126\/scitranslmed.abn6868 (2022).","journal-title":"Sci Transl Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker TL","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep 36, 109400, doi:10.1016\/j.celrep.2021.109400 (2021).","journal-title":"Cell Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026","author":"Hassan AO","year":"2020","unstructured":"Hassan, A. O. et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell 183, 169\u2013184 e113, doi:10.1016\/j.cell.2020.08.026 (2020)."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000886","article-title":"SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters","volume":"4","author":"Selvaraj P","year":"2021","unstructured":"Selvaraj, P. et al. SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters. Life Sci Alliance 4, doi:10.26508\/lsa.202000886 (2021).","journal-title":"Life Sci Alliance"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"eabj7790","DOI":"10.1126\/scitranslmed.abj7790","article-title":"Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19","volume":"13","author":"D'Agnillo F","year":"2021","unstructured":"D'Agnillo, F. et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci Transl Med 13, eabj7790, doi:10.1126\/scitranslmed.abj7790 (2021).","journal-title":"Sci Transl Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/03009858211057197","article-title":"Hamster models of COVID-19 pneumonia reviewed: How human can they be?","volume":"59","author":"Gruber AD","year":"2022","unstructured":"Gruber, A. D., Firsching, T. C., Trimpert, J. & Dietert, K. Hamster models of COVID-19 pneumonia reviewed: How human can they be? Vet Pathol 59, 528\u2013545, doi:10.1177\/03009858211057197 (2022).","journal-title":"Vet Pathol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMc2209651","article-title":"Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection","volume":"387","author":"Havervall S","year":"2022","unstructured":"Havervall, S. et al. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. N Engl J Med 387, 1333\u20131336, doi:10.1056\/NEJMc2209651 (2022).","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.it.2021.09.003","article-title":"Differential roles of interferons in innate responses to mucosal viral infections","volume":"42","author":"Walker FC","year":"2021","unstructured":"Walker, F. C., Sridhar, P. R. & Baldridge, M. T. Differential roles of interferons in innate responses to mucosal viral infections. Trends Immunol 42, 1009\u20131023, doi:10.1016\/j.it.2021.09.003 (2021).","journal-title":"Trends Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"888897","DOI":"10.3389\/fimmu.2022.888897","article-title":"Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy","volume":"13","author":"Eskandarian Boroujeni M","year":"2022","unstructured":"Eskandarian Boroujeni, M. et al. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Front Immunol 13, 888897, doi:10.3389\/fimmu.2022.888897 (2022).","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.virol.2021.01.005","article-title":"The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters","volume":"556","author":"Stauft CB","year":"2021","unstructured":"Stauft, C. B., Lien, C. Z., Selvaraj, P., Liu, S. & Wang, T. T. The G614 pandemic SARS-CoV-2 variant is not more pathogenic than the original D614 form in adult Syrian hamsters. Virology 556, 96\u2013100, doi:10.1016\/j.virol.2021.01.005 (2021).","journal-title":"Virology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.30802\/AALAS-JAALAS-18-000032","article-title":"Comparison of Isoflurane, Ketamine-Dexmedetomidine, and Ketamine-Xylazine for General Anesthesia during Oral Procedures in Rice Rats (Oryzomys palustris)","volume":"58","author":"Jiron JM","year":"2019","unstructured":"Jiron, J. M. et al. Comparison of Isoflurane, Ketamine-Dexmedetomidine, and Ketamine-Xylazine for General Anesthesia during Oral Procedures in Rice Rats (Oryzomys palustris). J Am Assoc Lab Anim Sci 58, 40\u201349, doi:10.30802\/AALAS-JAALAS-18-000032 (2019).","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac264","article-title":"Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro","author":"Stauft CB","year":"2022","unstructured":"Stauft, C. B., Sangare, K. & Wang, T. T. Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro. J Infect Dis, doi:10.1093\/infdis\/jiac264 (2022).","journal-title":"J Infect Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen P","year":"2021","unstructured":"Chen, P. et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 384, 229\u2013237, doi:10.1056\/NEJMoa2029849 (2021).","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41541-021-00410-8","article-title":"MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge","volume":"6","author":"Meseda CA","year":"2021","unstructured":"Meseda, C. A. et al. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge. NPJ Vaccines 6, 145, doi:10.1038\/s41541-021-00410-8 (2021).","journal-title":"NPJ Vaccines"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2227555\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2227555\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T15:58:03Z","timestamp":1687622283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2227555\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":45,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2227555\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41467-023-39090-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2022,11,11]]},"subtype":"preprint"}}